Royalty Pharma (RPRX) Non Operating Investment Income (2020 - 2021)

Royalty Pharma (RPRX) reported Non Operating Investment Income of $11.8 million for Q3 2021, down 11.6% sequentially from $13.3 million in Q2 2021.

Royalty Pharma (RPRX) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Royalty Pharma (RPRX) has 2 years of Non Operating Investment Income data on file, last reported at $11.8 million in Q3 2021.

For the quarter ending Q3 2021, Non Operating Investment Income changed N/A year-over-year to $11.8 million; the trailing twelve-month figure through Sep 2021 stood at $50.2 million (changed N/A YoY), and the FY2020 full-year result was $20.6 million, changed N/A from the prior year.
Non Operating Investment Income eased to $11.8 million in Q3 2021, from $13.3 million in the prior quarter.
In the past five years, Non Operating Investment Income ranged from a high of $20.6 million in Q4 2020 to a low of $4.6 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Oculis Holding AG	67,132.22 Bn	67,131.94 Bn	-	-
2	Nanobiotix	1,910.87 Bn	1,910.81 Bn	-	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-	-
4	BeOne Medicines	471.60 Bn	466.80 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.71 Bn	114.46 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.83 Bn	61.07 Bn	3.31 Bn	-
7	Belite Bio	62.74 Bn	62.74 Bn	-	-
8	Argenx Se	55.83 Bn	50.65 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.33 Bn	34.32 Bn	959.66 Mn	-
10	Royalty Pharma	25.78 Bn	25.17 Bn	-	-

Download Data